Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Receptor, Epidermal Growth Factor

abstract

  • In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug. This observation should help guide the search for more effective therapy against a specific subset of lung cancers.

publication date

  • May 18, 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC549606

Digital Object Identifier (DOI)

  • 10.1371/journal.pmed.0020073

PubMed ID

  • 15737014

Additional Document Info

start page

  • e73

volume

  • 2